Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Participants had adequately controlled asthma (mean ACT or cACT score = 21.6 ± 2.8) at baseline.
|
31371165 |
2020 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over half (55.7%) had uncontrolled asthma as measured by ACT/cACT; 13.9% had a normal ACT/cACT score but were uncontrolled using the Asthma Control Questionnaire and 20.2% were controlled on both measures but had received oral steroids in the past year for asthma.
|
30772471 |
2019 |
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Statistically significant reductions in self-reported environmental asthma triggers and health improvements were found in the following areas: doctor visits, use of antibiotics for chest problems, respiratory symptoms and quality of life indicators, and asthma control (ACT score).
|
30831256 |
2019 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discovered DMRs annotated to genes implicated in allergic asthma, Th2 activation and eosinophilia (EPX, IL4, IL13) and genes previously associated with asthma and IgE in EWAS of blood (ACOT7, SLC25A25).
|
31300640 |
2019 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the contrary, gender, FEV<sub>1</sub>, FEV<sub>1</sub>/FVC ratio, FEF<sub>25-75</sub>, ACT, VAS of breathing perception, oral corticosteroid use, and asthma severity grade were associated with the asthma control grade.
|
31047107 |
2019 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among women who completed the ACT during the clinical interview, the 50% of women who experienced worsening asthma during pregnancy (6/12) had an ACT score below 20.
|
29692816 |
2018 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Asthma control was assessed per the 2012 GINA guidelines and the ACT questionnaire.
|
29724395 |
2018 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Validity indicators were calculated at different C-ACT cut-points to determine those most appropriate for predicting controlled and uncontrolled asthma.
|
29223149 |
2018 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No significant correlations were observed between FeNO levels and other parameters (Asthma Control Test [ACT] score or forced expiratory volume in one second [FEV<sub>1</sub>]) in mean and percentage change of values under treatment of asthma; however, significant positive correlations were found between ACT scores and FEV<sub>1</sub>.
|
29110960 |
2017 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The percentages of children showing controlled asthma (C-ACT) were 18% (pre-treatment), 69% (post-treatment), and 44% (follow-up).
|
27736038 |
2017 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-ACT can be validity used to monitor asthma control.
|
28984253 |
2017 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In FP/FORM-treated patients aged ≥12 years, asthma control (Asthma Control Test™ [ACT]), incidence of severe exacerbations, lung function, quality of life (asthma quality of life questionnaire [AQLQ]) and adverse events (AEs) were assessed over one year.
|
28947024 |
2017 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Measurements included fraction of exhaled nitric oxide (FENO, ppb), dynamic and static lung function, and bronchial provocation with methacholine (PD:20) and mannitol (PD:15), as well as an evaluation of respiratory symptoms using the asthma control test (C-ACT).
|
28636794 |
2017 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency of VDR ApaI aa genotype was significantly higher in controlled asthma group (n=92) than uncontrolled asthma group (n=35), according to C-ACT (24.5% vs 0.0%, p<0.001) and GINA (32.7% vs 7.5%, p=0.001).
|
25353337 |
2014 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association of ACT -17 A/T polymorphism with Alzheimer's disease: a meta-analysis.
|
22272609 |
2013 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have investigated whether the -86 C/T promoter polymorphism in CHRNA7 gene, the signal peptide polymorphism of the alpha1-antichymotripsin (ACT) gene or the APOE genotype are associated with an increased risk of mild cognitive impairment (MCI) or affect the risk of evolution to Alzheimer's disease (AD).
|
18078695 |
2009 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACT levels were higher in AD patients than in CIND or controls.
|
18991685 |
2008 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that the ACT gene may affect AAO and disease duration of AD.
|
16137793 |
2006 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACT is a major component of the senile plaques (SP) characteristic of Alzheimer's disease (AD).
|
15530656 |
2004 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, polymorphisms within the ApoE and alpha1-ACT gene have been implicated in the aetiology of AD and s-IBM.
|
15159602 |
2004 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACT measurements in cerebrospinal fluid from an additional 34 AD cases and 16 controls showed elevated levels (p = 0.02) in AD.
|
12509851 |
2003 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results from GENEHUNTER, SOLAR, and ACT software packages are compared for the quantitative trait immunoglobulin E (IgE) using chromosome 5 asthma familial data from Oxfordshire (England), Perth (Australia), and Freiburg (Germany), and using the genome-wide German data.
|
11793783 |
2001 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated a common signal peptide polymorphism in the alpha 1-antichymotrypsin (ACT) gene in 125 sporadic Alzheimer disease (AD) patients and 141 healthy control subjects in Chinese Han population.
|
10893483 |
2000 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACT serum levels were higher in women with AD that in female and male controls.
|
10629358 |
2000 |